Correction Volume 13, Issue 4 pp 6228—6230

Yinjie Su^{1, *,} , Zehu Du^{2, *,} , Guanglei Zhong^3, , Yiyao Ya^1,4, , B Junming^1, , Juanyi Shi^1, , Luping Chen^5, , Wen Dong^1, , Tianxin Lin^1, ,

Received: February 17, 2020       Accepted: February 24, 2020       Published: February 27, 2020      

Copyright: © 2021 Su et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: The authors requested the replacement of Figure 1D, E, F, G, Figure 2I, Figure 3H and Table 1. The authors made changes to improve presentation of the panels. They removed duplications and overlaps of the images with minor modifications of the original data. The revised table reflects the updated properties of the patients sample pool.

These corrections do not change the content of the publication and do not affect the conclusion of this research. The authors apologize for the unintentional mistakes.

The corrected Figures and Table are provided below.

Figure 1. Lower circ5912 levels are associated with advanced bladder cancer. (D) Expression of circ5912 in 45 paired bladder cancer tissues; 58 bladder cancer tissues were evaluated and analyzed by: (E) stages, (F) tumor grade and (G) metastasis; (H) overall survival of 43 bladder cancer patients in following was analyzed based on the level of circ5912.

Figure 2. Silencing circ5912 promotes bladder cancer cell growth and metastasis in vitro. (I) migration and invasion were assessed by counting cells that were able to penetrate the trans-well membrane, scale bar: 25μm.

Figure 3. Overexpression of circ5912 suppresses bladder cancer growth and metastasis. (H) migration and invasion were assessed by counting cells that penetrated the trans-well membrane, scale bar: 25μm.

Table 1. Relationship between circ5912 level and clinical characteristics in bladder cancer.

Total		Patients	Expression of cic5912
			High	Low	p
Age(mean)		56	52.52	59.48	0.200
Gender
	Male	46	20	26	0.052
	Female	12	9	3
Tumor stage
	Tis/Ta/T1	28	20	8	0.003
	T2	21	8	13
	T3/T4	9	1	8
Grade
	High	27	6	21	<0.001
	Low	31	23	8
Number of tumors
	Solitary	41	21	20	0.773
	Multiple	17	8	9
Lymph node metastasis
	Negative	26	18	8	0.008
	Positive	32	11	21
Follow-up (month, mean)		38.465	43.095	34.045	0.016